폐쇄형 시스템 바이오프로세싱 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Closed System Bioprocessing Market Summary

The global closed system bioprocessing market size was valued at USD 10.95 billion in 2025 and is projected to reach USD 21.37 billion by 2033, expanding at a CAGR of 8.90% from 2026 to 2033. This growth is primarily driven by the increasing adoption of single-use technologies, rising biologics and cell & gene therapy production, and the growing need to minimize contamination risks while improving operational efficiency in biomanufacturing processes.

Reduced Contamination Risk & Improved Product Quality

Closed system bioprocessing is witnessing strong demand due to its ability to significantly reduce contamination risks in biologics manufacturing. By operating within sealed, sterile pathways, these systems minimize human intervention and environmental exposure, which is critical for sensitive biologics such as monoclonal antibodies, vaccines, and cell therapies. This helps prevent batch failures, product recalls, and regulatory non-compliance while ensuring consistent sterility.

In addition, closed systems enhance product quality and process reliability by reducing manual handling and enabling standardized, automated workflows. They support reproducibility, lower batch rejection rates, and align with GMP requirements for contamination control and traceability, driving increased adoption among biopharmaceutical manufacturers worldwide.

Rising Demand for Biologics, Vaccines & Advanced Therapies

The rising global demand for biologics, such as monoclonal antibodies, recombinant proteins, vaccines, and biosimilars, is a key factor driving the adoption of closed system bioprocessing. As biologics are highly sensitive to contamination and process variability, sealed and sterile processing environments are essential to maintain product quality, stability, and regulatory compliance, prompting increased investment from biopharmaceutical manufacturers.

In addition, the rapid growth of advanced therapies, including cell and gene therapies and personalized treatments, is further boosting demand for closed systems. These technologies support aseptic, automated, and flexible manufacturing workflows, enabling consistent product quality, faster production timelines, and reduced contamination risks in advanced therapeutic production.

Global Closed System Bioprocessing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global closed system bioprocessing market report on the basis of product, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Bioreactors
• Fermenters
• Mixing Systems
• Filtration Systems
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical Production
• Vaccine Manufacturing
• Cell And Gene Therapy
• Regenerative Medicine
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotech Companies
• Contract Manufacturing Organizations
• Research & Academic Institutes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Reduced contamination risk & improved product quality
    • 3.2.1.2. Rising demand for biologics, vaccines & advanced therapies
    • 3.2.1.3. Technological advancements
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High operational costs
    • 3.2.2.2. Stringent regulatory and validation hurdles
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. Closed System Bioprocessing Market: Product Business Analysis

• 4.1. Product Segment Dashboard
• 4.2. Global Closed System Bioprocessing Market Product Movement Analysis
• 4.3. Global Closed System Bioprocessing Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Bioreactors
  • 4.4.1. Global Bioreactors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Fermenters
  • 4.5.1. Global Fermenters Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Mixing Systems
  • 4.6.1. Global Mixing Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Filtration Systems
  • 4.7.1. Global Filtration Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Closed System Bioprocessing Market: Application Business Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global Closed System Bioprocessing Market Application, Movement Analysis
• 5.3. Global Closed System Bioprocessing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Biopharmaceutical Production
  • 5.4.1. Global Biopharmaceutical Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Vaccine Manufacturing
  • 5.5.1. Global Vaccine Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Cell and Gene Therapy
  • 5.6.1. Global Cell and Gene Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Regenerative Medicine
  • 5.7.1. Global Regenerative Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Closed System Bioprocessing Market: End Use Business Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Global Closed System Bioprocessing Market End Use Movement Analysis
• 6.3. Global Closed System Bioprocessing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Pharmaceutical & Biotech Companies
  • 6.4.1. Global Pharmaceutical & Biotech Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Contract Manufacturing Organizations
  • 6.5.1. Global Contract Manufacturing Organizations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Research & Academic Institutes
  • 6.6.1. Global Research & Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Closed System Bioprocessing Market: Regional Estimates & Trend Analysis by Product Type, Technology, Application, & End Use.

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. North America Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Australia Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Thailand Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. South Korea
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. South Korea Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Saudi Arabia Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. UAE Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait Closed System Bioprocessing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Share/ Position Analysis, 2025
• 8.4. Participant's Overview
  • 8.4.1. Thermo Fisher Scientific
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Sartorius AG
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Merck KGaA
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. GE Healthcare (Cytiva)
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Danaher Corporation
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Eppendorf AG
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Lonza Group
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Corning Incorporated
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Pall Corporation
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Applikon Biotechnology
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives
  • 8.4.11. PBS Biotech
    • 8.4.11.1. Overview
    • 8.4.11.2. Financial Performance
    • 8.4.11.3. Product Benchmarking
    • 8.4.11.4. Strategic Initiatives
  • 8.4.12. Miltenyi Biotec
    • 8.4.12.1. Overview
    • 8.4.12.2. Financial Performance
    • 8.4.12.3. Product Benchmarking
    • 8.4.12.4. Strategic Initiatives
  • 8.4.13. Fujifilm Diosynth Biotechnologies
    • 8.4.13.1. Overview
    • 8.4.13.2. Financial Performance
    • 8.4.13.3. Product Benchmarking
    • 8.4.13.4. Strategic Initiatives